NCT03837899: Durvalumab and Tremelimumab for Pediatric Malignancies

NCT03837899
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: up to 17 Years (Child)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients over 17 years of age
https://ClinicalTrials.gov/show/NCT03837899

Comments are closed.

Up ↑